~~<i id='4D319CBEAE'><strike id='4D319CBEAE'><tt id='4D319CBEAE'><pre id='4D319CBEAE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：explore 2025-09-29 23:03:42 - browse：1394

A close up photograph of an IV drop in a Portland hospital – politics and policy coverage from STAT — A patient receives an IV drip at a hospital in Portland, Ore. Jenny Kane/AP

WASHINGTON — A new White House task force on drug shortages held a rare in-person meeting last Friday with representatives from hospitals, drugmakers, pharmacies, and others in the drug supply chain to brainstorm policies for stemming shortages of cancer drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Galapagos to make CAR

explore

hotspot

leisure time

focus

explore

MANDELNGAN/AFPviaGettyImagesWASHINGTON—Associalmediasiteswerefloodedwithmisleadingpostsaboutvaccines

WSS

WATCH: Why do bright lights make us see spots?

Cherokee Nation medical school graduates its first class

Novo Nordisk testing Wegovy against alcohol

Supreme Court to hear if Covid misinformation is protected speech

Food makers to regulators: Ultra

The United States must get value

hotspot

Wikipedia

explore

Duchenne breakthrough therapy leaves behind pioneering families

Hospitals consider fixing cancer drug shortages on their own

Medical records are filled with copy

Regeneron agrees to White House price limits on anti

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Long Covid needs a new name — and a new frame

Affirmative action in medical school literally saved lives

Hottest summer in 2,000 years puts focus on extreme heat, health

Bright Health sells Medicare Advantage business to Molina

Boston hospital trains restaurant workers on naloxone for overdoses

hotspot

Lilly’s weekly insulin works as well as daily products, new studies show

Obesity drug from Roche shows promise in early study

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

How to make the FDA’s new prescription one

New weight loss drugs vying to be the next Wegovy or Mounjaro

Acelyrin, a rare IPO success, stumbles in its first big test

hotspot

leisure time

focus

explore